SNIPR Expr
Alternative Names: SNIPR-ExprLatest Information Update: 02 Feb 2024
At a glance
- Originator SNIPR Biome
- Class Anti-inflammatories; Gene therapies; Obesity therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Colitis; Inflammatory bowel diseases; Obesity
Most Recent Events
- 16 Jan 2024 SNIPR Expr is available for licensing as of 16 Jan 2024. https://www.sniprbiome.com/partnering (SNIPR Biome pipeline, January 2024)
- 16 Jan 2024 Early research in Inflammatory bowel diseases in Denmark (unspecified route) prior to January 2024 (SNIPR Biome pipeline, January 2024)
- 16 Jan 2024 Early research in Colitis in Denmark (unspecified route) prior to January 2024 (SNIPR Biome pipeline, January 2024)